JP2001151692A - Method and agent for treating disease infected with canine parvovirus - Google Patents
Method and agent for treating disease infected with canine parvovirusInfo
- Publication number
- JP2001151692A JP2001151692A JP2000271173A JP2000271173A JP2001151692A JP 2001151692 A JP2001151692 A JP 2001151692A JP 2000271173 A JP2000271173 A JP 2000271173A JP 2000271173 A JP2000271173 A JP 2000271173A JP 2001151692 A JP2001151692 A JP 2001151692A
- Authority
- JP
- Japan
- Prior art keywords
- day
- canine parvovirus
- canine
- feline interferon
- parvovirus infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 25
- 241000701931 Canine parvovirus Species 0.000 title claims description 48
- 201000010099 disease Diseases 0.000 title abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 5
- 241000282324 Felis Species 0.000 claims abstract description 40
- 108010045648 interferon omega 1 Proteins 0.000 claims abstract description 22
- 241000282465 Canis Species 0.000 claims abstract description 19
- 208000008071 Parvoviridae Infections Diseases 0.000 claims description 40
- 206010057343 Parvovirus infection Diseases 0.000 claims description 39
- 108010050904 Interferons Proteins 0.000 claims description 18
- 102000014150 Interferons Human genes 0.000 claims description 18
- 229940079322 interferon Drugs 0.000 claims description 18
- 238000001802 infusion Methods 0.000 claims description 16
- 238000001990 intravenous administration Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 239000003792 electrolyte Substances 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 description 23
- 230000036528 appetite Effects 0.000 description 23
- 235000019789 appetite Nutrition 0.000 description 23
- 206010047700 Vomiting Diseases 0.000 description 19
- 230000008673 vomiting Effects 0.000 description 19
- 210000000265 leukocyte Anatomy 0.000 description 15
- 206010012735 Diarrhoea Diseases 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 238000010254 subcutaneous injection Methods 0.000 description 6
- 239000007929 subcutaneous injection Substances 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002636 symptomatic treatment Methods 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000255789 Bombyx mori Species 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 241001032492 Canine parvovirus 2 Species 0.000 description 2
- 241000714201 Feline calicivirus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229960004841 cefadroxil Drugs 0.000 description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000003090 exacerbative effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000010006 flight Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000026775 severe diarrhea Diseases 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- KQFRUSHJPKXBMB-BHDSKKPTSA-N Ala-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 KQFRUSHJPKXBMB-BHDSKKPTSA-N 0.000 description 1
- OSRZOHXQCUFIQG-FPMFFAJLSA-N Ala-Phe-Pro Chemical compound C([C@H](NC(=O)[C@@H]([NH3+])C)C(=O)N1[C@H](CCC1)C([O-])=O)C1=CC=CC=C1 OSRZOHXQCUFIQG-FPMFFAJLSA-N 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 1
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 description 1
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 1
- JZRLLSOWDYUKOK-SRVKXCTJSA-N Asn-Asp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N JZRLLSOWDYUKOK-SRVKXCTJSA-N 0.000 description 1
- QNJIRRVTOXNGMH-GUBZILKMSA-N Asn-Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(N)=O QNJIRRVTOXNGMH-GUBZILKMSA-N 0.000 description 1
- UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 1
- SOYOSFXLXYZNRG-CIUDSAMLSA-N Asp-Arg-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O SOYOSFXLXYZNRG-CIUDSAMLSA-N 0.000 description 1
- DXQOQMCLWWADMU-ACZMJKKPSA-N Asp-Gln-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O DXQOQMCLWWADMU-ACZMJKKPSA-N 0.000 description 1
- DRCOAZZDQRCGGP-GHCJXIJMSA-N Asp-Ser-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DRCOAZZDQRCGGP-GHCJXIJMSA-N 0.000 description 1
- 208000006339 Caliciviridae Infections Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XABFFGOGKOORCG-CIUDSAMLSA-N Cys-Asp-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XABFFGOGKOORCG-CIUDSAMLSA-N 0.000 description 1
- KZZYVYWSXMFYEC-DCAQKATOSA-N Cys-Val-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KZZYVYWSXMFYEC-DCAQKATOSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000701925 Feline parvovirus Species 0.000 description 1
- KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 description 1
- IXFVOPOHSRKJNG-LAEOZQHASA-N Gln-Asp-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IXFVOPOHSRKJNG-LAEOZQHASA-N 0.000 description 1
- MAGNEQBFSBREJL-DCAQKATOSA-N Gln-Glu-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N MAGNEQBFSBREJL-DCAQKATOSA-N 0.000 description 1
- XJKAKYXMFHUIHT-AUTRQRHGSA-N Gln-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N XJKAKYXMFHUIHT-AUTRQRHGSA-N 0.000 description 1
- IRDASPPCLZIERZ-XHNCKOQMSA-N Glu-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N IRDASPPCLZIERZ-XHNCKOQMSA-N 0.000 description 1
- IESFZVCAVACGPH-PEFMBERDSA-N Glu-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O IESFZVCAVACGPH-PEFMBERDSA-N 0.000 description 1
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 1
- GRHXUHCFENOCOS-ZPFDUUQYSA-N Glu-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)O)N GRHXUHCFENOCOS-ZPFDUUQYSA-N 0.000 description 1
- WVWZIPOJECFDAG-AVGNSLFASA-N Glu-Phe-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N WVWZIPOJECFDAG-AVGNSLFASA-N 0.000 description 1
- YZPVGIVFMZLQMM-YUMQZZPRSA-N Gly-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN YZPVGIVFMZLQMM-YUMQZZPRSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- RGPWUJOMKFYFSR-QWRGUYRKSA-N His-Gly-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O RGPWUJOMKFYFSR-QWRGUYRKSA-N 0.000 description 1
- PGRPSOUCWRBWKZ-DLOVCJGASA-N His-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CN=CN1 PGRPSOUCWRBWKZ-DLOVCJGASA-N 0.000 description 1
- PYNPBMCLAKTHJL-SRVKXCTJSA-N His-Pro-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O PYNPBMCLAKTHJL-SRVKXCTJSA-N 0.000 description 1
- GBMSSORHVHAYLU-QTKMDUPCSA-N His-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CN=CN1)N)O GBMSSORHVHAYLU-QTKMDUPCSA-N 0.000 description 1
- 101000619708 Homo sapiens Peroxiredoxin-6 Proteins 0.000 description 1
- USXAYNCLFSUSBA-MGHWNKPDSA-N Ile-Phe-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N USXAYNCLFSUSBA-MGHWNKPDSA-N 0.000 description 1
- 102100036479 Interferon omega-1 Human genes 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- HBJZFCIVFIBNSV-DCAQKATOSA-N Leu-Arg-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O HBJZFCIVFIBNSV-DCAQKATOSA-N 0.000 description 1
- IGUOAYLTQJLPPD-DCAQKATOSA-N Leu-Asn-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IGUOAYLTQJLPPD-DCAQKATOSA-N 0.000 description 1
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- ZDJQVSIPFLMNOX-RHYQMDGZSA-N Leu-Thr-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZDJQVSIPFLMNOX-RHYQMDGZSA-N 0.000 description 1
- AEDWWMMHUGYIFD-HJGDQZAQSA-N Leu-Thr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O AEDWWMMHUGYIFD-HJGDQZAQSA-N 0.000 description 1
- JGKHAFUAPZCCDU-BZSNNMDCSA-N Leu-Tyr-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=C(O)C=C1 JGKHAFUAPZCCDU-BZSNNMDCSA-N 0.000 description 1
- FLCMXEFCTLXBTL-DCAQKATOSA-N Lys-Asp-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N FLCMXEFCTLXBTL-DCAQKATOSA-N 0.000 description 1
- SQRLLZAQNOQCEG-KKUMJFAQSA-N Lys-Tyr-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 SQRLLZAQNOQCEG-KKUMJFAQSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028140 Mucous stools Diseases 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 101100205189 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-5 gene Proteins 0.000 description 1
- 102100022239 Peroxiredoxin-6 Human genes 0.000 description 1
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 1
- PBWNICYZGJQKJV-BZSNNMDCSA-N Phe-Phe-Cys Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CS)C(O)=O PBWNICYZGJQKJV-BZSNNMDCSA-N 0.000 description 1
- FKKHDBFNOLCYQM-FXQIFTODSA-N Pro-Cys-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O FKKHDBFNOLCYQM-FXQIFTODSA-N 0.000 description 1
- XZONQWUEBAFQPO-HJGDQZAQSA-N Pro-Gln-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XZONQWUEBAFQPO-HJGDQZAQSA-N 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 1
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 1
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 1
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 1
- WCTYCXZYBNKEIV-SXNHZJKMSA-N Trp-Glu-Ile Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)=CNC2=C1 WCTYCXZYBNKEIV-SXNHZJKMSA-N 0.000 description 1
- FDKDGFGTHGJKNV-FHWLQOOXSA-N Tyr-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FDKDGFGTHGJKNV-FHWLQOOXSA-N 0.000 description 1
- AGDDLOQMXUQPDY-BZSNNMDCSA-N Tyr-Tyr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O AGDDLOQMXUQPDY-BZSNNMDCSA-N 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明はイヌのパルボウイル
ス感染症の治療に関するものである。The present invention relates to the treatment of parvovirus infection in dogs.
【０００２】[0002]
【従来の技術】感染しやすく致死性の高いイヌパルボウ
イルス−２型（ＣＰＶ−２）が１９７８年以来広く世界
中に伝播した。同ウイルスのサブタイプの出現に伴い、
以前に比較してイヌパルボウイルスは一般的に軽症にな
り、死亡率も低くなったが、依然として重篤なイヌのウ
イルス病である。特に幼若なイヌでは本疾病に感染する
率が高く、しばしば死亡することがある。体温の急激な
上昇や、下痢、嘔吐、食欲廃絶など重篤な症状を呈す
る。白血球数（ＷＢＣ）も急激に減少する。BACKGROUND OF THE INVENTION Canine parvovirus type 2 (CPV-2), which is easily infected and highly lethal, has been widely transmitted worldwide since 1978. With the emergence of subtypes of the virus,
Canine parvovirus is generally milder and has lower mortality compared to previous years, but remains a serious canine viral disease. In particular, young dogs have a high incidence of the disease and often die. Severe symptoms such as a sharp rise in body temperature, diarrhea, vomiting, and loss of appetite. The white blood cell count (WBC) also decreases sharply.
【０００３】イヌパルボウイルス感染症に関しては、ワ
クチンも開発され、予防法も確立されてきたが、ワクチ
ンの投与が開始できる時点までの幼少期の子犬での感染
による発症をワクチンでは阻止できないため、幼若犬で
の発症に対する対策には役にたたない。With respect to canine parvovirus infection, vaccines have been developed and preventive measures have been established, but vaccines cannot prevent the onset of infection in childhood puppies until the time when vaccine administration can be started. It does not help control the onset in young dogs.
【０００４】イヌパルボウイルスは、非常に抵抗性の強
いウイルスであり、通常の環境中で数ヶ月から数年間生
存するため、自然発症例は依然少なくない。特に集団と
して飼育される場合は猛威を振るうことがあり、ブリー
ダーやペットショップでの本感染症による死亡が大きな
問題となっている。[0004] Canine parvovirus is a very resistant virus, and survives for several months to several years in a normal environment. In particular, when bred in groups, they can be violent, and death from this infection at breeders and pet shops has become a major problem.
【０００５】従来、日本でネコインターフェロン−ωの
製剤が上市されるまでは、イヌパルボウイルス感染症に
対しては、対症療法と維持療法として電解質輸液と２次
感染防止に広域性抗生物質が使用されているにすぎなか
った。しかし、ネコインターフェロン−ωの製剤であ
る”インターキャット”がネコカリシウイルス感染症の
治療薬として日本で承認され、上市されてからは、ネコ
パルボウイルス感染症に対する野外臨床試験で治療効果
が確認され、救命効果と臨床症状の改善、ＷＢＣの低下
抑制と急激なＷＢＣの上昇回復効果が注目された。Until the preparation of feline interferon-ω was launched in Japan, canine parvovirus infections were treated with electrolytes as a symptomatic treatment and maintenance therapy, and a broad-spectrum antibiotic was used to prevent secondary infections. It was just being done. However, since feline interferon-ω preparation “Intercat” was approved in Japan as a therapeutic agent for feline calicivirus infection and launched on the market, its therapeutic effect was confirmed in field clinical trials against feline parvovirus infection. Attention was paid to the effect of improving life-saving effects and clinical symptoms, suppressing the reduction of WBC, and rapidly increasing and recovering WBC.
【０００６】さらに、”インターキャット”は、種特異
性のあるネコインターフェロン−ωではあるが、イヌに
対しても効果があることが腫瘍細胞を用いる実験室研究
での抗腫瘍効果についての研究で明らかになり、イヌパ
ルボウイルス感染症に対しても効果があることがｉｎ
ｖｉｖｏのビーグル犬に対するウイルス強制感染後の治
療試験で確認された。あわせてイヌパルボウイルス感染
症に対する野外臨床試験が実施され、従来からの対症療
法と維持療法に対して、ネコインターフェロン−ωを併
用使用した療法の試験で、治療効果が確認された。[0006] Furthermore, although "intercat" is a feline interferon-ω with species specificity, it is also effective for dogs in a study on the antitumor effect in a laboratory study using tumor cells. It is clear that it is effective against canine parvovirus infection in
It was confirmed in a treatment test after a virus forced infection of a beagle dog in vivo. In addition, a field clinical test for canine parvovirus infection was carried out, and a therapeutic effect was confirmed in a test of a therapy using feline interferon-ω in combination with conventional symptomatic treatment and maintenance therapy.
【０００７】対症療法群での死亡率は６１．９％（１３
／２１）に対して、ネコインターフェロン−ωを１日１
回体重ｋｇあたり、１．０ＭＵ（１００万単位）または
２．５ＭＵを３日間連日静脈中投与する方法では、死亡
率は、２４．０％（１２／５０）となり著明な救命効果
が確認された。また、臨床症状の改善を指標とする有効
性判定でも、対症療法群の３３．３％の有効率に対し
て、ネコインターフェロン−ω治療群では６６．０％の
有効率が確認された。The mortality rate in the symptomatic treatment group was 61.9% (13%).
/ 21), feline interferon-ω 1 day
With the method of intravenously administering 1.0 MU (1 million units) or 2.5 MU per day for 3 days per kg of body weight, the mortality rate was 24.0% (12/50), and a remarkable life-saving effect was confirmed. Was. In addition, in the efficacy evaluation using improvement of clinical symptoms as an index, an efficacy rate of 66.0% was confirmed in the feline interferon-ω treatment group, compared to an efficacy rate of 33.3% in the symptomatic treatment group.
【０００８】イヌパルボウイルスの簡便な迅速診断薬が
承認されてからは、早期にイヌパルボウイルス感染を診
断することが可能となり、従来のように下痢、嘔吐など
の臨床症状やＷＢＣの低下で本症と診断される前に、早
期にウイルス感染犬と判定することが出来るようになっ
てきた。そこで、イヌパルボウイルス感染症の早期診断
とネコインターフェロン−ωを用いた従来の治療とによ
る併用療法により、イヌパルボウイルス感染症による死
亡率はさらに１０％近くまで低下し、さらなる救命効果
が達成された。投与経路の静脈内投与と皮下投与との比
較試験で、静脈内投与の方が、皮下投与よりも臨床症状
の改善効果が高いことも確認された。ネコインターフェ
ロン−ωの用法、用量は１日１回、体重１ｋｇあたり
１．０ＭＵを３日間投与する方法であった。[0008] After the approval of a simple and rapid diagnostic reagent for canine parvovirus, it is possible to diagnose canine parvovirus infection at an early stage, and to reduce the clinical symptoms such as diarrhea and vomiting and the decrease in WBC. Before being diagnosed with the disease, it has become possible to quickly determine that the dog is a virus-infected dog. Thus, the combination therapy of early diagnosis of canine parvovirus infection and conventional treatment using feline interferon-ω further reduces the mortality rate of canine parvovirus infection to nearly 10% and achieves a further life-saving effect. Was. In a comparative study of intravenous administration and subcutaneous administration of the administration route, it was also confirmed that intravenous administration has a higher effect of improving clinical symptoms than subcutaneous administration. Feline interferon-ω was administered once daily at a dose of 1.0 MU / kg body weight for 3 days.
【０００９】[0009]
【発明が解決しようとする課題】以上の通り、ネコイン
ターフェロン−ωの使用により、従来の対症療法に比較
し、イヌパルボウイルス感染症の治療効果が飛躍的に向
上できた。しかし、依然として救命できず、死亡する症
例も１０％近く残されており、さらなる治療方法の改良
が望まれている。As described above, the use of feline interferon-ω significantly improved the therapeutic effect of canine parvovirus infection as compared with conventional symptomatic treatment. However, there are still about 10% of cases that cannot be saved and die, and further improvement of treatment methods is desired.
【００１０】[0010]
【課題を解決するための手段】本発明の課題は、イヌパ
ルボウイルス感染症の治療、特に救命効果の高い優れた
治療方法および治療剤を提供することにある。SUMMARY OF THE INVENTION An object of the present invention is to provide an excellent method for treating canine parvovirus infectious diseases, particularly, a highly effective life-saving agent and a therapeutic agent.
【００１１】発明者らは上記の課題を解決すべく検討し
た結果、ネコインターフェロン−ωを含んでなる治療剤
とイヌ乾燥プラズマとを併用することによるイヌパルボ
ウイルス感染症の治療方法を見出し、本発明に至った。
すなわち本発明は下記の構成を有する。 （１）ネコインターフェロンおよびイヌ乾燥プラズマを
イヌパルボウイルスに投与することを特徴とするイヌパ
ルボウイルス感染症治療方法。 （２）ネコインターフェロンがネコインターフェロン−
ωであることを特徴とする（１）記載のイヌパルボウイ
ルス感染症治療方法。 （３）ネコインターフェロン−ωが配列番号：１に示し
たアミノ酸配列を有する糖鎖を結合したネコインターフ
ェロン−ωであることを特徴とする（２）記載のイヌパ
ルボウイルス感染症治療方法。 （４）ネコインターフェロン−ωの投与量が、イヌの体
重あたり０．５〜２．５ＭＵ／ｋｇであり、１日１回以
上、連続して３日以上、静脈中および／または皮下に投
与することを特徴とする（１）〜（３）のいずれかに記
載のイヌパルボウイルス感染症治療方法。 （５）イヌ乾燥プラズマが、イヌパルボウイルスワクチ
ンを投与した健康なイヌの血漿の凍結乾燥品を含むこと
を特徴とする（１）から（４）のいずれか記載のイヌパ
ルボウイルス感染症治療方法。 （６）イヌ乾燥プラズマの投与が、１日１回以上、連続
して３日以上、静脈中に点滴投与することを特徴とする
（１）から（５）のいずれか記載のイヌパルボウイルス
感染症治療方法。 （７）電解質輸液および／または広域性抗生物質を併用
することを特徴とする（１）〜（６）のいずれか記載の
イヌパルボウイルス感染症治療方法。 （８）ネコインターフェロンおよびイヌ乾燥プラズマを
含むイヌパルボウイルス感染症治療剤。The present inventors have studied to solve the above problems, and as a result, have found a method for treating canine parvovirus infection by using a therapeutic agent containing feline interferon-ω together with canine dry plasma. Invented the invention.
That is, the present invention has the following configuration. (1) A method for treating canine parvovirus infection, which comprises administering feline interferon and canine dry plasma to canine parvovirus. (2) Feline interferon is feline interferon-
(1) The method for treating canine parvovirus infection according to (1), which is ω. (3) The method for treating canine parvovirus infection according to (2), wherein the feline interferon-ω is a feline interferon-ω having a sugar chain having the amino acid sequence shown in SEQ ID NO: 1. (4) The dose of feline interferon-ω is 0.5 to 2.5 MU / kg per body weight of dog, and is administered intravenously and / or subcutaneously at least once a day, continuously for three days or more. The method for treating canine parvovirus infection according to any one of (1) to (3), wherein (5) The method for treating canine parvovirus infection according to any one of (1) to (4), wherein the canine dry plasma includes a lyophilized product of healthy canine plasma administered with a canine parvovirus vaccine. . (6) The canine parvovirus infection according to any one of (1) to (5), wherein the administration of the canine dry plasma is performed by intravenous infusion at least once a day for three consecutive days or more. Treatment method. (7) The method for treating canine parvovirus infection according to any one of (1) to (6), wherein an electrolyte transfusion and / or a broad spectrum antibiotic is used in combination. (8) A therapeutic agent for canine parvovirus infection, including feline interferon and canine dry plasma.
【００１２】[0012]
【発明の実施の形態】本発明では、ネコインターフェロ
ンとイヌ乾燥プラズマをイヌに投与することが重要であ
る。これらを併用することで、イヌパルボウイルス感染
症の治療効果を著しく高めることが出来る。DETAILED DESCRIPTION OF THE INVENTION In the present invention, it is important to administer feline interferon and canine dry plasma to dogs. By using these together, the therapeutic effect of canine parvovirus infection can be significantly increased.
【００１３】本発明で使用するネコインターフェロン
は、ネコインターフェロン−ω（ω（オメガ）型ネコイ
ンターフェロン）が好ましく、天然型、化学合成により
製造されるもの、遺伝子組換え技術により製造されるも
ののいずれであってもよい。The feline interferon used in the present invention is preferably feline interferon-ω (ω (omega) feline interferon), and may be any of a natural type, one produced by chemical synthesis, and one produced by genetic recombination technology. There may be.
【００１４】具体的には、”インターキャット”（東レ
（株）製）の商品名で市販されている遺伝子組換え技術
で製造されたω型ネコインターフェロンが挙げられる。Specifically, there is a ω-type feline interferon produced by a gene recombination technique which is commercially available under the trade name of “INTERCAT” (manufactured by Toray Industries, Inc.).
【００１５】この”インターキャット”は、ネコのネコ
カリシウイルス感染症の治療薬として承認されて実用化
されているものであり、ω型ネコインターフェロンの遺
伝子を組換えした昆虫ウイルスの組換えバキュロウイル
スをカイコ幼虫に感染させ、カイコ生体中に産出したも
のを抽出・分離・精製して得られた、配列番号：１に示
した１７０個のアミノ酸配列を有する糖鎖を結合したイ
ンターフェロンを主成分とするものである。This "intercat" has been approved and commercialized as a therapeutic agent for feline calicivirus infectious disease in cats, and is a recombinant baculovirus of an insect virus in which the gene of ω-type feline interferon is recombined. Is infected with silkworm larvae, and the interferon bound to a sugar chain having the amino acid sequence of 170 amino acids shown in SEQ ID NO: 1 obtained by extracting, separating and purifying those produced in the living body of the silkworm is used as a main component. Is what you do.
【００１６】しかしながら、本発明のネコインターフェ
ロンは必ずしも上記遺伝子組換え型のネコインターフェ
ロンに限定されるものではない。However, the feline interferon of the present invention is not necessarily limited to the above-mentioned recombinant feline interferon.
【００１７】ネコインターフェロン−ωの投与量は、イ
ヌの体重あたり０．５〜２．５ＭＵ／ｋｇであることが
好ましい。この範囲で投与することにより有効にイヌパ
ルボウイルス感染症を治療することが出来る。The dose of feline interferon-ω is preferably 0.5 to 2.5 MU / kg per dog body weight. By administering in this range, canine parvovirus infection can be effectively treated.
【００１８】また、投与回数は、１日１回以上、連続し
て３日以上投与することが好ましい。この範囲で投与す
ることでより有効にイヌパルボウイルス感染症の治療を
行うことが出来る。The number of times of administration is preferably at least once a day, and continuously for three or more days. By administering in this range, canine parvovirus infection can be more effectively treated.
【００１９】また、投与の方法は、静脈中および／また
は皮下に投与するのが好ましい。The method of administration is preferably intravenous and / or subcutaneous.
【００２０】ネコインターフェロンを注射投与する場合
は、好ましくは、ネコインターフェロン−ωを主剤とす
る製剤を、用時に生理食塩液や輸液その他の溶液に溶解
して得られる溶液を注射投与するのが好ましい。投与ル
ートは皮下、静脈内、筋肉内のいずれでもよく、好まし
くは静脈内、皮下への注射が簡便で実用的である。When feline interferon is administered by injection, it is preferable to inject a solution obtained by dissolving a preparation containing feline interferon-ω as a main component in a physiological saline solution, an infusion solution or another solution at the time of use. . The route of administration may be any of subcutaneous, intravenous and intramuscular routes. Preferably, intravenous or subcutaneous injection is simple and practical.
【００２１】また、本発明で使用するイヌ乾燥プラズマ
は、イヌパルボウイルスワクチンを投与した健康なイヌ
の血漿の凍結乾燥品を含むことが好ましい。動物用医薬
品として日生研（株）が製造し、武田薬品工業（株）が
「乾燥犬プラズマ」として販売している。健康なイヌの
血漿を加熱処理して凍結乾燥した後、減圧下に封じたも
のであり、りん酸緩衝食塩液の溶解用液で溶解して用い
られる。The dry dog plasma used in the present invention preferably contains a lyophilized product of healthy dog plasma to which a canine parvovirus vaccine has been administered. It is manufactured by Nisseiken Co., Ltd. as an animal drug, and sold by Takeda Pharmaceutical Co., Ltd. as "Dried Dog Plasma". Healthy dog plasma is heat-treated, freeze-dried, sealed under reduced pressure, and dissolved in a phosphate buffered saline solution for use.
【００２２】イヌ乾燥プラズマの投与は、１日１回以
上、連続して３日以上、静脈中に点滴投与するのが好ま
しい。通常は、市販のイヌ乾燥プラズマ製剤の１０ｍｌ
溶解液を１回２ｍｌ以上、１日１回以上、好ましくは２
回以上、静脈に点滴する。The administration of dry plasma of dogs is preferably performed by intravenous infusion at least once a day, three consecutive days or more. Typically, 10 ml of a commercially available canine dry plasma formulation
Dissolve 2 ml or more of the lysate once a day or more, preferably
Inject vein more than once.
【００２３】また、本発明においては、電解質輸液およ
び／または広域性抗生物質を併用することが好ましい。In the present invention, it is preferable to use electrolyte infusion and / or broad-spectrum antibiotics in combination.
【００２４】さらに、本発明は、ネコインターフェロン
およびイヌ乾燥プラズマを含むイヌパルボウイルス感染
症治療剤を提供する。Further, the present invention provides a therapeutic agent for canine parvovirus infection, which comprises feline interferon and canine dry plasma.
【００２５】本発明の治療方法によれば、有効にイヌパ
ルボウイルス感染症を治療することが出来、重篤な副作
用も認められない。According to the treatment method of the present invention, canine parvovirus infection can be effectively treated, and no serious side effects are observed.
【００２６】[0026]
【実施例】以下に本発明の実施例を示す。Examples of the present invention will be described below.
【００２７】ここで使用するネコインターフェロン−ω
としては、１９９４年２月から”インターキャット”の
商品名で市販されている組換えバキュロウイルスをカイ
コに感染させてカイコ生体内で産生させた遺伝子組換え
型のネコインターフェロン−ωを主剤とする製剤を用い
た。Feline interferon-ω used here
The main agent is transgenic feline interferon-ω produced by infecting silkworms with a recombinant baculovirus commercially available under the trade name “Intercat” from February 1994 and producing them in vivo. The formulation was used.
【００２８】実施例１ ゴールデンレトリバーの生後５０日の雌、体重３ｋｇ
が、黒色軟便、嘔吐、食欲なしの来院時症状を呈し、イ
ヌパルボウイルス感染症の疑いがあった。初日（０日
目）に”インターキャット”１ＭＵ／ｋｇを皮下注射
し、トリプリセンを経口投与した。翌日（１日目）は、
下痢と腐臭嘔吐を呈し、食欲、元気いずれもなかった。
ＷＢＣは１１０００に低下していた。パルボウイルス感
染診断キットのパルボチェックにより陽性であった。輸
液（ソルデムＴ３）を点滴し、”インターキャット”
１．２５ＭＵ／ｋｇ静脈中投与を２回実施し、武田薬品
工業（株）販売のイヌ乾燥プラズマを０．３ｍｌ ２回
投与し、抗生剤バイトリルを２回筋肉中に注射した。翌
２日目は、下痢は３〜４回となり腐臭嘔吐はなくなり、
食欲も少しでてきたが、１日目と同じ治療を実施した。
３日目は、粘血便多数回となり、腐臭がした。嘔吐はな
く、食欲は少しのままであった、前日と同じ治療を実施
した。ＷＢＣは４２００に低下していた。４日目は軟便
１回となり、嘔吐はなく、食欲がでてきた。”インター
キャット”の投与量を１．０ＭＵ／ｋｇに減らし、皮下
注射した。その他、輸液、イヌ乾燥プラズマ、抗生剤の
投与は前日と同じとした。５日目には、嘔吐、下痢とも
になくなり、食欲があった。ＷＢＣは８０００に回復し
た。前日と同じ治療を継続した。６日目は元気が回復し
た。”インターキャット”の皮下注射１ＭＵ／ｋｇと抗
生剤の投与を継続し、イヌ乾燥プラズマの投与は前日ま
での５日連続で終了した。７日目は黒色普通便となり、
食欲があった。７〜９日目まで”インターキャット”の
１ＭＵ／ｋｇ皮下注射と抗生剤の投与を継続した。８、
９日目ともに状態は良好であった。Example 1 Female 50 days after birth of golden retriever, body weight 3 kg
However, she presented with symptoms of black loose stool, vomiting, and lack of appetite at the time of the visit, and she was suspected of having a canine parvovirus infection. On the first day (day 0), 1 MU / kg of "Intercat" was injected subcutaneously, and triplicene was orally administered. The next day (the first day)
He had diarrhea and odor and vomiting, and neither appetite nor energy.
WBC had dropped to 11,000. The result was positive by parvocheck of the parvovirus infection diagnostic kit. Infusion (Soldem T3) is infused and "Intercat"
Intravenous administration of 1.25 MU / kg was performed twice, 0.3 ml of dog dry plasma sold by Takeda Pharmaceutical Co., Ltd. was administered twice, and the antibiotic baitril was injected twice into the muscle. On the next 2nd day, diarrhea was 3-4 times and there was no odor and vomiting,
He had a little appetite, but did the same treatment as on day one.
On the third day, the mucous stools became numerous times and the odor went off. No vomiting, little appetite, same treatment as the previous day. WBC had dropped to 4200. On the fourth day, she had one loose stool, no vomiting and appetite. The dose of "Intercat" was reduced to 1.0 MU / kg and injected subcutaneously. Infusion, administration of canine dry plasma and antibiotics were the same as the previous day. On the fifth day, she had no vomiting or diarrhea and had an appetite. WBC recovered to 8000. The same treatment as the previous day was continued. On the sixth day, he recovered. Administration of 1 MU / kg subcutaneous injection of "intercat" and antibiotics was continued, and administration of dog dry plasma was completed for 5 consecutive days up to the previous day. On the 7th day, black regular flights became
I had an appetite. From day 7 to day 9 MU / kg subcutaneous injection of "Intercat" and administration of antibiotics were continued. 8,
On day 9 the condition was good.
【００２９】以上、”インターキャット”を９日間投与
し、イヌ乾燥プラズマ１日２回投与を５日間併用して、
イヌパルボウイルス感染症を治療、回復した。As described above, "intercat" was administered for 9 days, and dog dry plasma was administered twice a day for 5 days.
Treated and resolved canine parvovirus infection.
【００３０】実施例２ ロングチワワの生後約２ヶ月の雄、体重１．１ｋｇが、
軟便、嘔吐、食欲なしで来院した。ＷＢＣは１０７０
０。パルボチェックで陽性。輸液（ソルデムＴ３）の点
滴と抗生剤の経口投与に加えて、”インターキャット”
２．５ＭＵ／ｋｇを静脈中投与し、イヌ乾燥プラズマ
（武田薬品工業（株）販売）２ｍｌを点滴。翌日１日目
には、嘔吐が無くなり、食欲は少しであるが元気であ
り、便排泄はなかった。”インターキャット”２．５Ｍ
Ｕ／ｋｇを皮下注射に切り替え、その他、イヌ乾燥プラ
ズマ、輸液、抗生剤投与は０日目に同じとした。２日目
は、食欲が無く、強制給餌し、１日目と同じ治療をし
た。ＷＢＣは８０００に低下したが元気はあった。３，
４日目ともに元気ありであるが食欲無しで強制給餌し
た。２日目と同じ治療をした。５日目は食欲が戻った
が、１日目以降便排泄なしが継続し、嘔吐はなかった。
前日と同じ治療を実施した。６日目には普通便２回とな
り、食欲も戻り、元気があった。前日と同じ治療をした
後、退院した。Example 2 A long-chihuahua male about 2 months old, weighing 1.1 kg,
He came to the hospital without loose stools, vomiting and appetite. WBC is 1070
0. Positive on parvo check. In addition to infusion of infusion (Soldem T3) and oral administration of antibiotics, "Intercat"
2.5 MU / kg was intravenously administered, and 2 ml of dog dry plasma (available from Takeda Pharmaceutical Co., Ltd.) was instilled. On the next day, on the first day, she had no vomiting, had a little appetite, was fine, and had no stool excretion. "Intercat" 2.5M
U / kg was switched to subcutaneous injection, and dog dry plasma, infusion and antibiotic administration were the same on day 0. On the second day, she had no appetite, was forcibly fed, and was treated the same as the first day. WBC dropped to 8000, but he was fine. 3,
On the fourth day, they were fine but were forced to feed without appetite. The same treatment was given on the second day. The appetite returned on the fifth day, but no fecal excretion continued from the first day, and no vomiting occurred.
The same treatment as the previous day was administered. On the sixth day, the regular flights were twice and my appetite returned, and I was fine. After the same treatment as the previous day, he was discharged.
【００３１】以上、”インターキャット”を初回２．５
ＭＵ／ｋｇ静脈注射、２日目以降２．５ＭＵ／ｋｇの皮
下注射に変更し、３日から６日目まで１ＭＵ／ｋｇに減
量して７日間連日投与した。イヌ乾燥プラズマは２ｍｌ
／日を７日間連続投与した。イヌパルボウイルス感染症
を臨床症状の重篤悪化させることなく、治療回復した。As described above, "Intercat" was first used for 2.5
Intravenous injection of MU / kg was changed to 2.5 MU / kg subcutaneous injection from the second day, and the dose was reduced to 1 MU / kg from the third day to the sixth day and administered every day for 7 days. 2 ml of dry dog plasma
/ Day for 7 consecutive days. Canine parvovirus infection recovered without severe clinical symptoms.
【００３２】実施例３ ゴールデンレトリバーの生後５０日の雌、体重２．３ｋ
ｇが、下痢、嘔吐、食欲なしで来院した。ＷＢＣは２６
１００。パルボチェック陽性。コクシジウム陽性であっ
た。初日（０日目）に”インターキャット”２．５ＭＵ
／ｋｇを静脈中注射し、翌日（１日目）に皮下注射に切
り替え、３日目から１ＭＵ／ｋｇに減量して６日目まで
連続投与した。イヌ乾燥プラズマ（武田薬品工業（株）
販売）０．３ｍｌを０日目〜３日目まで４日間連日点滴
した。輸液（ソルデムＴ３）の点滴とジメトキシン２５
ｍｇ／ｋｇを２回／日静脈中投与を０から３日目まで４
日間連続で行った。４日目にトリブリセンの経口投与を
１回行った。Example 3 Female 50 days after birth of golden retriever, body weight 2.3 k
g came to the hospital without diarrhea, vomiting and appetite. WBC is 26
100. Parvo check positive. Coccidial was positive. On the first day (day 0) "Intercat" 2.5 MU
/ Kg was injected intravenously, and switched to subcutaneous injection on the next day (day 1), the dose was reduced to 1 MU / kg from day 3 and continuously administered until day 6. Dog dry plasma (Takeda Pharmaceutical Co., Ltd.)
0.3 ml was instilled every day for 4 days from day 0 to day 3. Infusion (Soldem T3) drip and dimethoxine 25
mg / kg 2 times / day intravenous administration from 0 to 3 days
Performed for consecutive days. On the fourth day, one oral administration of tribrisene was performed.
【００３３】嘔吐は２日目にはなくなり、下痢も２日目
には普通便となり、食欲も２日目から回復した。３日目
から５日目まで咳が少しあり、４日目と５日目は鼻汁が
少しあったが、６日目には回復した。Vomiting disappeared on the second day, diarrhea also became normal on the second day, and appetite recovered from the second day. There was a slight cough from days 3 to 5, a slight nasal discharge on days 4 and 5, but a recovery on day 6.
【００３４】以上、イヌパルボウイルス感染症を悪化さ
せないで治療できた。As described above, the present invention was able to treat canine parvovirus infection without exacerbating it.
【００３５】実施例４ ミニロングダックスの生後約２ヶ月の雌、体重１．１ｋ
ｇが、下痢、腐臭、元気・食欲なしで来院した。ＷＢＣ
は１５２００であり、パルボチェックで陽性であっ
た。”インターキャット”を初日（０日目）に２．５Ｍ
Ｕ／ｋｇ静脈中投与し、翌日１日目から８日目まで２．
５ＭＵ／ｋｇ皮下投与した。イヌ乾燥プラズマ（武田薬
品工業（株）販売）２ｍｌを０日目から４日目まで静脈
中投与。輸液（ソルデムＴ３）の点滴とタイセゾリンの
静脈中投与を０〜４日目まで連日実施した。５日目にセ
ファドロキシルを経口投与した。Example 4 Mini long duck female approximately 2 months old, weight 1.1k
g came to the hospital without diarrhea, rotten smell, cheerfulness and appetite. WBC
Was 15200 and was positive by Parvocheck. "Intercat" on the first day (day 0) 2.5M
U / kg intravenous administration, from day 1 to day 8 on the next day.
5 MU / kg was administered subcutaneously. 2 ml of dog-dried plasma (available from Takeda Pharmaceutical Co., Ltd.) was intravenously administered from day 0 to day 4. Infusion of infusion (Soldem T3) and intravenous administration of tisezoline were performed daily from day 0 to day 4. On day 5, cefadroxil was administered orally.
【００３６】嘔吐は２日目に回復、元気は１日目に回復
し、食欲は３日目に改善した。Vomiting recovered on the second day, energy recovered on the first day, and appetite improved on the third day.
【００３７】以上、イヌパルボウイルス感染症を悪化さ
せることなく早期に回復治療できた。As described above, the recovery treatment could be carried out at an early stage without exacerbating canine parvovirus infection.
【００３８】実施例５ ミニロングダックスの生後約２ヶ月の雌、体重１．２ｋ
ｇが、未消化下痢便、嘔吐、元気・食欲なしで来院し
た。ＷＢＣは１４２００であった。”インターキャッ
ト”を初日（０日目）〜２日目まで２．５ＭＵ／ｋｇ静
脈中投与し、３日目から６日目まで１ＭＵ／ｋｇに減量
し、皮下注射した。イヌ乾燥プラズマ（武田薬品工業
（株）販売）２ｍｌを０日目から４日目まで１日２回静
脈中に点滴した。輸液（ソルデムＴ３）の点滴静注を０
〜４日目まで実施した。抗生剤（バイトリル ５ｍｇ／
ｋｇ）を１日２回、１日目から４日目まで連日皮下投与
し、５，６日目には経口投与した。Example 5 Mini long duck female approximately 2 months old, weight 1.2 k
g visited the hospital without undigested diarrheal stool, vomiting, and cheerfulness / appetite. WBC was 14,200. “Intercat” was intravenously administered at 2.5 MU / kg from the first day (day 0) to the second day, reduced to 1 MU / kg from the third day to the sixth day, and injected subcutaneously. 2 ml of dog-dried plasma (available from Takeda Pharmaceutical Co., Ltd.) was instilled intravenously twice a day from day 0 to day 4. No intravenous drip of infusion (Soldem T3)
Performed until ま で 4 days. Antibiotics (Biteril 5mg /
kg) was administered subcutaneously twice a day from day 1 to day 4 daily, and orally on days 5 and 6.
【００３９】１日目はＷＢＣが５９００まで低下し、嘔
吐、激しい下痢、腐臭、食欲・元気なしであった。パル
ボチェックは陽性であった。２日目に嘔吐と下痢がなく
なり、飲水欲も出、食欲も少し回復した。３日目には食
欲も回復し、４日目以降元気・食欲ありで、便も正常化
した。On the first day, the WBC decreased to 5,900, and vomiting, severe diarrhea, rotten odor, appetite and lack of energy were observed. Parvocheck was positive. On the second day, vomiting and diarrhea disappeared, the desire to drink water increased, and the appetite recovered slightly. On the third day, the appetite was restored, and on the fourth day, she was well and appetite, and her stool was normalized.
【００４０】以上、イヌパルボウイルス感染症が臨床症
状の早期で回復した。As described above, canine parvovirus infection was recovered at an early stage of clinical symptoms.
【００４１】実施例６ ポメラニアンの生後約２ヶ月の雄、体重８５０ｇが、下
痢、嘔吐、元気・食欲なしで来院した。ＷＢＣは２５７
００であった。パルボチェックで陽性であった。”イン
ターキャット”を初日（０日目）〜７日目まで２．５Ｍ
Ｕ／ｋｇ静脈中投与した。イヌ乾燥プラズマ（武田薬品
工業（株）販売）２ｍｌを０日目から７日目まで１日２
回静脈中に点滴した。輸液（ソルデムＴ３）の点滴静注
を０〜７日目まで連日実施した。ビクタス ０．２ｍｌ
を１日２回、１日目から７日目まで連日皮下投与した。
７日目にセファドロキシルを経口投与した。Example 6 A Pomeranian male, approximately 2 months old, weighing 850 g, visited the clinic without diarrhea, vomiting, energy and appetite. WBC is 257
00. Positive on parvocheck. "Intercat" 2.5M from the first day (day 0) to the 7th day
U / kg was administered intravenously. 2 ml of dog-dried plasma (sold by Takeda Pharmaceutical Co., Ltd.) from day 0 to day 7
Intravenous infusion into the vein. Intravenous drip infusion (Soldem T3) was performed daily from day 0 to day 7. Victorus 0.2ml
Was administered subcutaneously twice daily from day 1 to day 7.
On the 7th day, cefadroxil was administered orally.
【００４２】４日目には嘔吐がなくなり、元気は回復し
たが、激しい下痢、腐臭、食欲なしであったが７日目に
回復した。On the fourth day, vomiting disappeared and the patient recovered, but without severe diarrhea, odor and appetite, but recovered on the seventh day.
【００４３】幼若で体重の軽いイヌではあったが、死亡
することなく、回復した。Although he was a young and light dog, he recovered without dying.
【００４４】[0044]
【発明の効果】ネコインターフェロンとイヌ乾燥プラズ
マの投与を併用することで、イヌパルボウイルス感染症
を有効に治療することが出来る。EFFECTS OF THE INVENTION The combined use of feline interferon and canine dry plasma can effectively treat canine parvovirus infection.
【００４５】[0045]
【配列表】 SEQUENCE LISTING <110> 東レ株式会社 <120> イヌパルボウイルス感染症治療方法および治療剤 <130> ０５Ａ０００７１ <160> １ <210> 1 <211> 170 <212> PRT <213> cat <400> 1 Cys Asp Leu Pro Gln Thr His Gly Leu Leu Asn Arg Arg Ala Leu 5 10 15 Thr Leu Leu Gly Gln Met Arg Arg Leu Pro Ala Ser Ser Cys Gln 20 25 30 Lys Asp Arg Asn Asp Phe Ala Phe Pro Gln Asp Val Phe Gly Gly 35 40 45 Asp Gln Ser His Lys Ala Gln Ala Leu Ser Val Val His Val Thr 50 55 60 Asn Gln Lys Ile Phe His Phe Phe Cys Thr Glu Ala Ser Ser Ser 65 70 75 Ala Ala Trp Asn Thr Thr Leu Leu Glu Glu Phe Cys Thr Gly Leu 80 85 90 Asp Arg Gln Leu Thr Arg Leu Glu Ala Cys Val Leu Gln Glu Val 95 100 105 Glu Glu Gly Glu Ala Pro Leu Thr Asn Glu Asp Ile His Pro Glu 110 115 120 Asp Ser Ile Leu Arg Asn Tyr Phe Gln Arg Leu Ser Leu Tyr Leu 125 130 135 Gln Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Ile Val Arg Ala 140 145 150 Glu Ile Met Arg Ser Leu Tyr Tyr Ser Ser Thr Ala Leu Gln Lys 155 160 165 Arg Leu Arg Ser Glu 170[Sequence list] SEQUENCE LISTING <110> Toray Industries, Inc. <120> Canine parvovirus infectious disease treatment method and therapeutic agent <130> 05A00071 <160> 1 <210> 1 <211> 170 <212> PRT <213> cat < 400> 1 Cys Asp Leu Pro Gln Thr His Gly Leu Leu Asn Arg Arg Ala Leu 5 10 15 Thr Leu Leu Gly Gln Met Arg Arg Leu Pro Ala Ser Ser Cys Gln 20 25 30 Lys Asp Arg Asn Asp Phe Ala Phe Pro Gln Asp Val Phe Gly Gly 35 40 45 Asp Gln Ser His Lys Ala Gln Ala Leu Ser Val Val His Val Thr 50 55 60 Asn Gln Lys Ile Phe His Phe Phe Cys Thr Glu Ala Ser Ser Ser 65 70 75 Ala Ala Trp Asn Thr Thr Leu Leu Glu Glu Phe Cys Thr Gly Leu 80 85 90 Asp Arg Gln Leu Thr Arg Leu Glu Ala Cys Val Leu Gln Glu Val 95 100 105 Glu Glu Gly Glu Ala Pro Leu Thr Asn Glu Asp Ile His Pro Glu 110 115 120 Asp Ser Ile Leu Arg Asn Tyr Phe Gln Arg Leu Ser Leu Tyr Leu 125 130 135 Gln Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Ile Val Arg Ala 140 145 150 Glu Ile Met Arg Ser Leu Tyr Tyr Ser Ser Thr Ala Leu Gln Lys 155 160 165 Arg Leu Ar g Ser Glu 170
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） //(Ｃ１２Ｎ 7/04 Ａ６１Ｋ 37/66 Ｇ Ｃ１２Ｒ 1:92） Ｃ１２Ｎ 15/00 ＺＮＡＡ ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) // (C12N 7/04 A61K 37/66 G C12R 1:92) C12N 15/00 ZNAA
Claims (8)
ラズマをイヌパルボウイルスに投与することを特徴とす
るイヌパルボウイルス感染症治療方法。1. A method for treating canine parvovirus infection, comprising administering feline interferon and canine dry plasma to canine parvovirus.
ェロン−ωであることを特徴とする請求項１記載のイヌ
パルボウイルス感染症治療方法。2. The method for treating canine parvovirus infection according to claim 1, wherein the feline interferon is feline interferon-ω.
１に示したアミノ酸配列を有する糖鎖を結合したネコイ
ンターフェロン−ωであることを特徴とする請求項２記
載のイヌパルボウイルス感染症治療方法。3. Feline interferon-ω is SEQ ID NO:
3. The method for treating canine parvovirus infection according to claim 2, which is a feline interferon-ω having a sugar chain having the amino acid sequence shown in 1 above.
の体重あたり０．５〜２．５ＭＵ／ｋｇであり、１日１
回以上、連続して３日以上、静脈中および／または皮下
に投与することを特徴とする請求項１から３のいずれか
に記載のイヌパルボウイルス感染症治療方法。4. The dose of feline interferon is 0.5 to 2.5 MU / kg per dog body weight,
The method for treating canine parvovirus infection according to any one of claims 1 to 3, wherein the method is administered intravenously and / or subcutaneously at least once and continuously for at least three days.
スワクチンを投与した健康なイヌの血漿の凍結乾燥品を
含むことを特徴とする請求項１から４のいずれか記載の
イヌパルボウイルス感染症治療方法。5. The method for treating canine parvovirus infection according to any one of claims 1 to 4, wherein the canine dry plasma comprises a lyophilized product of healthy canine plasma administered with a canine parvovirus vaccine. .
上、連続して３日以上、静脈中に点滴投与することを特
徴とする請求項１から５のいずれか記載のイヌパルボウ
イルス感染症治療方法。6. The canine parvovirus infection according to any one of claims 1 to 5, wherein the administration of the canine dry plasma is performed by intravenous infusion at least once a day, continuously for three days or more. Treatment method.
質を併用することを特徴とする請求項１から６のいずれ
か記載のイヌパルボウイルス感染症治療方法。7. The method for treating canine parvovirus infection according to any one of claims 1 to 6, wherein an electrolyte infusion and / or a broad spectrum antibiotic is used in combination.
ラズマを含むイヌパルボウイルス感染症治療剤。8. A therapeutic agent for canine parvovirus infection, comprising feline interferon and canine dry plasma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000271173A JP2001151692A (en) | 1999-09-09 | 2000-09-07 | Method and agent for treating disease infected with canine parvovirus |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11-255264 | 1999-09-09 | ||
| JP25526499 | 1999-09-09 | ||
| JP2000271173A JP2001151692A (en) | 1999-09-09 | 2000-09-07 | Method and agent for treating disease infected with canine parvovirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001151692A true JP2001151692A (en) | 2001-06-05 |
Family
ID=26542104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000271173A Pending JP2001151692A (en) | 1999-09-09 | 2000-09-07 | Method and agent for treating disease infected with canine parvovirus |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001151692A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002036627A3 (en) * | 2000-11-03 | 2003-08-28 | Pbl Biomedical Lab | Interferons, uses and compositions related thereto |
| CN1313491C (en) * | 2005-08-09 | 2007-05-02 | 中国科学院微生物研究所 | Cat omega interferon and its coding gene and uses |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59225125A (en) * | 1983-04-06 | 1984-12-18 | ア−マ−・フア−マシユ−テイカル・カンパニ− | Improved intravenously administrable immunogloblin composition |
-
2000
- 2000-09-07 JP JP2000271173A patent/JP2001151692A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59225125A (en) * | 1983-04-06 | 1984-12-18 | ア−マ−・フア−マシユ−テイカル・カンパニ− | Improved intravenously administrable immunogloblin composition |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002036627A3 (en) * | 2000-11-03 | 2003-08-28 | Pbl Biomedical Lab | Interferons, uses and compositions related thereto |
| US7666995B2 (en) | 2000-11-03 | 2010-02-23 | Pestka Biomedical Laboratories | Interferons, uses and compositions related thereto |
| CN1313491C (en) * | 2005-08-09 | 2007-05-02 | 中国科学院微生物研究所 | Cat omega interferon and its coding gene and uses |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11298403B2 (en) | Therapeutic agent for inflammatory bowel disease | |
| RU2627451C9 (en) | Anti-inflammatory compositions | |
| AP628A (en) | New applications of lysozyme dimer. | |
| US20240158798A1 (en) | Non-viral gene/carrier complex for prevention or treatment of acute inflammatory disease | |
| CN112567037B (en) | TNF targeting aptamers for treating or diagnosing TNF-related inflammatory diseases and their uses | |
| JP2001151692A (en) | Method and agent for treating disease infected with canine parvovirus | |
| US10342852B2 (en) | Methods of reducing blood glucose or triglyceride levels by administration of METRNL protein | |
| CN102258537B (en) | Preparation method for chicken infectious bursal disease specific transfer factor | |
| JP3640980B2 (en) | Cat respiratory remedy and therapeutic method using the same | |
| EP1562571B1 (en) | Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection | |
| ES2929379T3 (en) | Methods for treating coronavirus infections | |
| ES2345244T3 (en) | COMPOSITIONS TO INCREASE THE SURVIVAL OF AQUATIC ANIMALS EXPOSED TO VIRUS RNA. | |
| CN114377127A (en) | Triple egg yolk antibody preparation and preparation method and application thereof | |
| RU2694210C1 (en) | Recombinant interferon-alpha dog preparation for use in therapy of natural viral infections of dogs | |
| JP4629964B2 (en) | Cattle digestive disease treatment | |
| CN102065873A (en) | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy | |
| CN1826133A (en) | Method for treating cancer patients undergoing chemotherapy | |
| RU2567802C2 (en) | Using pacap for treating viral infections in aquatic organisms | |
| JPH07165582A (en) | Agent for enhancing anticancer effect of immunnoanticancer agent | |
| US20230277650A1 (en) | Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv) | |
| RU2093177C1 (en) | Preparation for treatment and prophylaxis of sickness in mammals, birds and reptiles | |
| JP4748639B2 (en) | Liver disease treatment | |
| WO1998018484A1 (en) | Therapeutic agent and method for feline aids virus infections and feline atopic dermatitis | |
| BR112014004620B1 (en) | use of 'pituitary adenylate cyclase activating peptide', vaccine composition and vaccine combination | |
| CN108018311A (en) | Cachexia is treated by gene editing special target musculature MSTN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070320 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100427 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100817 |